Global Health Ltd (MEDANTA) is currently trading at 1,410.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Global Health Limited operates the Medanta brand, a multi-specialty tertiary and quaternary healthcare network spanning six hospitals across North and East India, with major capabilities in cardiac sciences, oncology, neurosciences, digestive sciences, orthopedics, liver transplant, and kidney and urology. Its ecosystem also includes clinics, laboratories, pharmacies, diagnostics, and continuity-of-care services. Q2 FY2027 delivered unusually strong operating leverage: revenue increased 33.6% year-on-year, while operating EBITDA rose 60.2% and margin expanded 418 basis points to 25.2%. This performance was driven primarily by patient volumes and improving utilization, rather than substantial price inflation, as ARPP increased only 2.7% during the quarter. The Noida hospital reached operating EBITDA breakeven in Q2 FY2027 after revenue climbed to INR 1,059 million, a notable inflection from losses in every prior reported quarter. This suggests that recently commissioned capacity can ramp faster than initially expected, potentially improving returns from the company’s broader pipeline of new hospitals. The company is pursuing an ambitious expansion cycle, with approximately 3,800 planned additional beds and estimated capex of INR 62,390 million over four to five years. Despite gross debt of INR 6,949 million, Global Health Limited retained a net cash position of INR 7,815 million at September 2026, providing financial flexibility for development. Cluster 2 hospitals, comprising Lucknow, Patna and Noida, became the principal growth engine, with Q2 revenue rising 63.2% and operating EBITDA increasing 110.0%. Their 31.7% margin exceeded Cluster 1’s 22.0%, showing that developing hospitals are already contributing disproportionately to incremental profitability as scale, case mix and occupancy improve.

Over the past 52 weeks, Global Health Ltd has traded between a low of ₹955.20 and a high of ₹1,542.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Global Health Ltd has a market capitalization of approximately 35,670.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Global Health Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 58.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 35,670.64 Cr, Global Health Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Global Health Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Global Health Ltd is 58.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Global Health Limited's board is scheduled to meet on November 3, 2026. The agenda is to consider and approve unaudited results for Q2 FY27 and the half year ended September 30, 2026.

Standalone net profit for Q1FY27 was ₹137.31 crore, compared with ₹151.96 crore in Q1FY26.

Global Health Ltd IPO listed on Nov 16, 2022 on NSE and BSE.

The plan to train one lakh Allied Health Professionals and the scheme to establish five regional medical tourism hubs are the most significant announcements, as they address key operational needs and growth drivers for Medanta.